Want to see DE:SBS full AI Analyst Report?

STRATEC Biomedical (SBS) Price & Analysis

6 Followers

SBS Stock Chart & Stats

€22.40

€0.10(0.34%)

At close: Jan 09 4:00 PM EST

€22.40

€0.10(0.34%)

Day’s Range― - ―

52-Week Range€16.30 - €33.10

Previous CloseN/A

Volume977.00

Average Volume (3M)15.55K

Market Cap

€233.39M

Enterprise Value€318.12M

Total Cash (Recent Filing)€23.74M

Total Debt (Recent Filing)€116.97M

Price to Earnings (P/E)―

Beta1.49

Next Earnings

Aug 14, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend Yield2.71%

Share Statistics

EPS (TTM)-0.27

Shares Outstanding12,157,841

10 Day Avg. Volume11,323

30 Day Avg. Volume15,548

Financial Highlights & Ratios

PEG Ratio11.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.09

P/FCF Ratio-28.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€28.00

Price Target Upside25.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)1.39

Revenue Forecast (FY)€263.72M

Bulls Say, Bears Say

Bulls Say

OEM/ODM Recurring Production ModelSTRATEC's OEM/ODM model creates durable, contract-driven revenue from development and series production. Multi-year partner relationships and recurring instrument build and service streams support predictable volume ramps, recurring aftermarket/consumables potential, and lower go-to-market risk versus selling under its own brand.

Improved Leverage And Equity BaseA solid equity base and recent leverage reduction provide financial flexibility to withstand cyclical weakness and fund inventory reduction or selective investments. Lower leverage reduces refinancing stress, supports continued R&D/capex delivery, and preserves optionality while management executes the H2 recovery plan.

Rebound In Operating And Free Cash FlowPositive operating and free cash flow despite margin pressure demonstrates cash conversion resilience, largely via working-capital improvements. Durable cash generation helps fund capex and inventory reduction targets, lowers short-term liquidity risk and gives management room to support product ramps without immediate external financing.

Bears Say

Multi-year Revenue DeclinePersistent top-line decline erodes scale and makes fixed-cost absorption harder, reducing long-term margin sustainability. Continued revenue weakness undermines the firm's ability to hit its 2025–2028 growth targets and increases reliance on a smaller set of partner ramps to restore sustainable growth.

Margin Compression And Net LossesSignificant margin deterioration and a swing to net losses weaken self-funding ability and slow deleveraging. If unfavorable mix and scalability issues persist, returning to targeted EBIT margins (~13% by 2028) will require sustained revenue recovery or structural cost improvements, both multi-quarter undertakings with execution risk.

Consumables Visibility & Elevated Inventory RiskUnfirm consumables demand threatens recurring high-margin revenue and adds downside to the H2 recovery case. Elevated inventory ties up cash, raises obsolescence risk and may force markdowns or write-offs. These structural working-capital issues can blunt margin recovery even if instrument shipments improve.

STRATEC Biomedical News

STRATEC Biomedical Balances Weak Q1 With Firm Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

STRATEC Biomedical Balances Q1 Setback With Solid Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

0RAR Upcoming Earnings Report: What to Expect?

STRATEC Biomedical (0RAR) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts...

4M ago

STRATEC Biomedical’s Earnings Call: Mixed Outlook

STRATEC Biomedical (($DE:SBS)) has held its Q3 earnings call. Read on for the main highlights of the call....

8M ago

STRATEC Biomedical (0RAR) Unveils Dividend Details for Q3: Mark Your Calendar!

STRATEC Biomedical (LSE: 0RAR) has declared, under its dividend policy, a yearly cash dividend in the amount of...

1y ago

0RAR Earnings this Week: How Will it Perform?

STRATEC Biomedical (0RAR) is scheduled to report 3rd quarter earnings on 10/25/2024, before the market opens. Regarding Q3...

2y ago

SBS FAQ

What was STRATEC Biomedical AG’s price range in the past 12 months?

STRATEC Biomedical AG lowest stock price was €16.30 and its highest was €33.10 in the past 12 months.

What is STRATEC Biomedical AG’s market cap?

STRATEC Biomedical AG’s market cap is €233.39M.

When is STRATEC Biomedical AG’s upcoming earnings report date?

STRATEC Biomedical AG’s upcoming earnings report date is Aug 14, 2026 which is in 30 days.

How were STRATEC Biomedical AG’s earnings last quarter?

Currently, no data Available

Is STRATEC Biomedical AG overvalued?

According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does STRATEC Biomedical AG pay dividends?

STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.71%. See more information on STRATEC Biomedical AG dividends here

What is STRATEC Biomedical AG’s EPS estimate?

STRATEC Biomedical AG’s EPS estimate is 0.19.

How many shares outstanding does STRATEC Biomedical AG have?

STRATEC Biomedical AG has 12,157,841 shares outstanding.

What happened to STRATEC Biomedical AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of STRATEC Biomedical AG?

Currently, no hedge funds are holding shares in DE:SBS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

STRATEC Biomedical Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
€28.00 (25.00% Upside)

Technicals

Top Smart Score Stocks >

Company Description

STRATEC Biomedical AG

Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.

STRATEC Biomedical (SBS) Earnings & Revenues

Historic Earnings Reports

SBS Stock 12 Month Forecast

Average Price Target

€28.00

▲(25.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"€15","38":"€38","20.75":"€20.8","26.5":"€26.5","32.25":"€32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,20.75,26.5,32.25,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,19.092307692307692,20.584615384615386,22.076923076923077,23.56923076923077,25.06153846153846,26.553846153846152,28.046153846153846,29.53846153846154,31.03076923076923,32.52307692307692,34.01538461538462,35.50769230769231,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,18.400000000000002,19.200000000000003,20,20.8,21.6,22.400000000000002,23.200000000000003,24,24.8,25.6,26.4,27.200000000000003,{"y":28,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.6,17.861538461538462,18.123076923076923,18.384615384615387,18.646153846153847,18.907692307692308,19.16923076923077,19.430769230769233,19.692307692307693,19.953846153846154,20.215384615384615,20.47692307692308,20.73846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.097,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.856,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.518,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.336,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.714,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.941,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.265,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.915,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.012,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.528,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >